These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

99 related items for PubMed ID: 20298204

  • 21. Peptide and protein mimetics inhibiting amyloid beta-peptide aggregation.
    Takahashi T, Mihara H.
    Acc Chem Res; 2008 Oct; 41(10):1309-18. PubMed ID: 18937396
    [Abstract] [Full Text] [Related]

  • 22. Retention of misfolded mutant transthyretin by the chaperone BiP/GRP78 mitigates amyloidogenesis.
    Sörgjerd K, Ghafouri B, Jonsson BH, Kelly JW, Blond SY, Hammarström P.
    J Mol Biol; 2006 Feb 17; 356(2):469-82. PubMed ID: 16376939
    [Abstract] [Full Text] [Related]

  • 23. Molecular pathogenesis of protein misfolding diseases: pathological molecular environments versus quality control systems against misfolded proteins.
    Naiki H, Nagai Y.
    J Biochem; 2009 Dec 17; 146(6):751-6. PubMed ID: 19643812
    [Abstract] [Full Text] [Related]

  • 24. [At last new light for the treatment of amyloidosis].
    Pettersson T.
    Duodecim; 2003 Dec 17; 119(12):1097-8. PubMed ID: 12868354
    [No Abstract] [Full Text] [Related]

  • 25. Targeted treatment for amyloidosis.
    Pepys-Vered ME, Pepys MB.
    Isr Med Assoc J; 2014 May 17; 16(5):277-80. PubMed ID: 24979830
    [No Abstract] [Full Text] [Related]

  • 26. Design of mechanism-based inhibitors of transthyretin amyloidosis: studies with biphenyl ethers and new structural templates.
    Gupta S, Chhibber M, Sinha S, Surolia A.
    J Med Chem; 2007 Nov 15; 50(23):5589-99. PubMed ID: 17948976
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Concentration of serum amyloid P component in the CSF as a possible marker of cerebral amyloid deposits in Alzheimer's disease.
    Hawkins PN, Rossor MN, Gallimore JR, Miller B, Moore EG, Pepys MB.
    Biochem Biophys Res Commun; 1994 Jun 15; 201(2):722-6. PubMed ID: 7516157
    [Abstract] [Full Text] [Related]

  • 30. Selection of peptides binding to the amyloid b-protein reveals potential inhibitors of amyloid formation.
    Schwarzman AL, Tsiper M, Gregori L, Goldgaber D, Frakowiak J, Mazur-Kolecka B, Taraskina A, Pchelina S, Vitek MP.
    Amyloid; 2005 Dec 15; 12(4):199-209. PubMed ID: 16399644
    [Abstract] [Full Text] [Related]

  • 31. Use of genetically altered mice to study the role of serum amyloid P component in amyloid deposition.
    Maeda S.
    Amyloid; 2003 Aug 15; 10 Suppl 1():17-20. PubMed ID: 14640037
    [Abstract] [Full Text] [Related]

  • 32. Circulating serum amyloid P component is the precursor of amyloid P component in tissue amyloid deposits.
    Baltz ML, Caspi D, Evans DJ, Rowe IF, Hind CR, Pepys MB.
    Clin Exp Immunol; 1986 Dec 15; 66(3):691-700. PubMed ID: 3568456
    [Abstract] [Full Text] [Related]

  • 33. Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations.
    Westermark P, Bergström J, Solomon A, Murphy C, Sletten K.
    Amyloid; 2003 Aug 15; 10 Suppl 1():48-54. PubMed ID: 14640042
    [Abstract] [Full Text] [Related]

  • 34. Preferential association of serum amyloid P component with fibrillar deposits in familial British and Danish dementias: similarities with Alzheimer's disease.
    Rostagno A, Lashley T, Ng D, Meyerson J, Braendgaard H, Plant G, Bojsen-Møller M, Holton J, Frangione B, Revesz T, Ghiso J.
    J Neurol Sci; 2007 Jun 15; 257(1-2):88-96. PubMed ID: 17374542
    [Abstract] [Full Text] [Related]

  • 35. Transgenic animal models of neurodegenerative diseases and their application to treatment development.
    Rockenstein E, Crews L, Masliah E.
    Adv Drug Deliv Rev; 2007 Sep 30; 59(11):1093-102. PubMed ID: 17869376
    [Abstract] [Full Text] [Related]

  • 36. [Transthyretin-its function and pathogenesis].
    Ando Y.
    Rinsho Byori; 2006 May 30; 54(5):497-502. PubMed ID: 16789420
    [Abstract] [Full Text] [Related]

  • 37. Novel therapeutic strategies for the treatment of protein-misfolding diseases.
    Rochet JC.
    Expert Rev Mol Med; 2007 Jun 28; 9(17):1-34. PubMed ID: 17597554
    [Abstract] [Full Text] [Related]

  • 38. Transthyretin stability as a key factor in amyloidogenesis: X-ray analysis at atomic resolution.
    Sebastião MP, Lamzin V, Saraiva MJ, Damas AM.
    J Mol Biol; 2001 Mar 02; 306(4):733-44. PubMed ID: 11243784
    [Abstract] [Full Text] [Related]

  • 39. Biophysical analyses of synthetic amyloid-beta(1-42) aggregates before and after covalent cross-linking. Implications for deducing the structure of endogenous amyloid-beta oligomers.
    Moore BD, Rangachari V, Tay WM, Milkovic NM, Rosenberry TL.
    Biochemistry; 2009 Dec 15; 48(49):11796-806. PubMed ID: 19916493
    [Abstract] [Full Text] [Related]

  • 40. Prevention of transthyretin amyloid disease by changing protein misfolding energetics.
    Hammarström P, Wiseman RL, Powers ET, Kelly JW.
    Science; 2003 Jan 31; 299(5607):713-6. PubMed ID: 12560553
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.